[go: up one dir, main page]

AR132029A2 - Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida - Google Patents

Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida

Info

Publication number
AR132029A2
AR132029A2 ARP240100516A ARP240100516A AR132029A2 AR 132029 A2 AR132029 A2 AR 132029A2 AR P240100516 A ARP240100516 A AR P240100516A AR P240100516 A ARP240100516 A AR P240100516A AR 132029 A2 AR132029 A2 AR 132029A2
Authority
AR
Argentina
Prior art keywords
formula
intermediate compound
octane
alkyl
carboxamide intermediate
Prior art date
Application number
ARP240100516A
Other languages
English (en)
Inventor
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Nakako Mitsuhashi
Yumiko Saito
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of AR132029A2 publication Critical patent/AR132029A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a procesos para preparar derivados de compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida representado por las fórmula (IV), (VI), en particular la fórmula (IV-1) y (VI-1). Reivindicación 1: Un proceso para producir un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida, en donde el compuesto intermediario tiene la siguiente fórmula (IV), caracterizado porque comprende: hacer reaccionar un compuesto representado por la fórmula (III) con un compuesto R³ONH₂ para producir un compuesto representado por la fórmula (IV) (en cada una de las fórmulas anteriores OBn es benciloxi, R¹ es 2,5-dioxopirrolidin-1-ilo, 1,3-dioxo-3a,4,7,7a-tetrahidro-1H-isoindol-2(3H)-ilo, 1,3-dioxohexahidro-1H-isoindol-2(3H)-ilo o 3,5-dioxo-4-azatriciclo[5.2.1.0²,⁶]dec-8-en-4-ilo, R³ es alquilo C₁₋₆ o heterociclilo, R³ se puede modificar con 0 a 5 R⁴, R⁴ se puede sustituir consecutivamente, aquí, R⁴ es alquilo C₁₋₆, heterociclilo, R⁵(R⁶)N- o un grupo protector, R⁵ y R⁶ son cada uno, de modo independiente, hidrógeno o alquilo C₁₋₆ o forman juntos heterociclilo, por otra parte, R³, R⁵ y R⁶ se pueden someter a cierre del anillo en una posición arbitraria).
ARP240100516A 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida AR132029A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08

Publications (1)

Publication Number Publication Date
AR132029A2 true AR132029A2 (es) 2025-05-21

Family

ID=52813113

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP140103759A AR097971A1 (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
ARP240100517A AR132030A2 (es) 2013-10-08 2024-03-01 Proceso de producción de formas cristalinas de derivado de diazabiciclooctano
ARP240100516A AR132029A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ARP240100515A AR132028A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP140103759A AR097971A1 (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
ARP240100517A AR132030A2 (es) 2013-10-08 2024-03-01 Proceso de producción de formas cristalinas de derivado de diazabiciclooctano

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP240100515A AR132028A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida

Country Status (22)

Country Link
US (5) US10131665B2 (es)
EP (4) EP3067355B1 (es)
JP (3) JP6617029B2 (es)
KR (2) KR102487297B1 (es)
CN (2) CN105612159A (es)
AR (4) AR097971A1 (es)
AU (1) AU2014332960B2 (es)
BR (2) BR112016006266B1 (es)
CA (2) CA2926071C (es)
DK (1) DK3067355T3 (es)
ES (2) ES2842225T3 (es)
HK (1) HK1219479A1 (es)
HU (1) HUE051925T2 (es)
IL (2) IL244969B (es)
MX (2) MX361659B (es)
MY (1) MY199066A (es)
NZ (5) NZ757222A (es)
RU (1) RU2695219C2 (es)
SG (1) SG11201602723RA (es)
TW (1) TWI673269B (es)
WO (1) WO2015053297A1 (es)
ZA (1) ZA201602054B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ701959A (en) 2012-05-30 2016-07-29 Meiji Seika Pharma Co Ltd Novel β-lactamase inhibitor and method for producing same
NZ718009A (en) * 2013-09-24 2018-03-23 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
EP3067355B1 (en) 2013-10-08 2020-12-16 Meiji Seika Pharma Co., Ltd. Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
WO2019016393A1 (en) 2017-07-21 2019-01-24 Antabio Sas CHEMICAL COMPOUNDS
JP7179058B2 (ja) * 2017-09-27 2022-11-28 Meiji Seikaファルマ株式会社 ジアザビシクロオクタン誘導体の剤形およびその生産プロセス
KR20200091395A (ko) * 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
EP3687993A1 (en) 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
EP3854786A4 (en) * 2018-09-21 2022-09-14 API Corporation PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES
WO2022014395A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (es) 1970-10-21 1975-12-10
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (es) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
ATE223916T1 (de) 1994-05-02 2002-09-15 Shionogi & Co Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
HUE032491T2 (en) 2010-12-22 2017-09-28 Meiji Seika Pharma Co Ltd An optically active diaza-bicyclooctane derivative and a process for its preparation
WO2012172368A1 (en) 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US8822450B2 (en) 2011-08-27 2014-09-02 Wockhardt Ltd. 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
KR101618424B1 (ko) 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
CN103781787B (zh) 2011-09-13 2015-09-23 沃克哈特有限公司 含氮化合物及其用途
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
NZ701959A (en) 2012-05-30 2016-07-29 Meiji Seika Pharma Co Ltd Novel β-lactamase inhibitor and method for producing same
MX368346B (es) * 2012-08-25 2019-09-27 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas.
NZ718009A (en) * 2013-09-24 2018-03-23 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
EP3067355B1 (en) 2013-10-08 2020-12-16 Meiji Seika Pharma Co., Ltd. Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
KR20160138538A (ko) 2014-03-29 2016-12-05 욱크하르트 리미티드 소듐 (2s, 5r)-6-(벤질옥시)-7-옥소-1,6-다이아자바이사이클로[3.2.1]옥테인-2-카복실레이트의 제조 방법
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation

Also Published As

Publication number Publication date
EP3613740A1 (en) 2020-02-26
TW201605855A (zh) 2016-02-16
RU2016116501A3 (es) 2018-07-12
US12221443B2 (en) 2025-02-11
AR132028A2 (es) 2025-05-21
KR102388529B1 (ko) 2022-04-20
US20250059191A1 (en) 2025-02-20
RU2019115119A3 (es) 2022-04-26
IL289275A (en) 2022-02-01
CA3110803C (en) 2022-09-27
HK1219479A1 (zh) 2017-04-07
US10604522B2 (en) 2020-03-31
US10131665B2 (en) 2018-11-20
US20190031659A1 (en) 2019-01-31
US20200181143A1 (en) 2020-06-11
RU2695219C2 (ru) 2019-07-22
AR097971A1 (es) 2016-04-20
NZ743374A (en) 2021-12-24
JP2021193107A (ja) 2021-12-23
HK1250030A1 (en) 2018-11-23
BR112016006266A2 (es) 2017-08-22
EP3299370B1 (en) 2021-11-24
KR102487297B1 (ko) 2023-01-12
CA2926071A1 (en) 2015-04-16
EP3067355A1 (en) 2016-09-14
TWI673269B (zh) 2019-10-01
US20220348578A1 (en) 2022-11-03
JPWO2015053297A1 (ja) 2017-03-09
NZ757221A (en) 2021-12-24
EP3067355A4 (en) 2017-04-26
MY199066A (en) 2023-10-12
CA3110803A1 (en) 2015-04-16
KR20160065871A (ko) 2016-06-09
RU2016116501A (ru) 2017-11-15
AU2014332960B2 (en) 2018-03-29
BR112016006266B1 (pt) 2022-11-16
HUE051925T2 (hu) 2021-04-28
KR20220054694A (ko) 2022-05-03
WO2015053297A1 (ja) 2015-04-16
JP7182677B2 (ja) 2022-12-02
CN105612159A (zh) 2016-05-25
ES2901198T3 (es) 2022-03-21
AR132030A2 (es) 2025-05-21
IL244969B (en) 2022-01-01
IL289275B (en) 2022-10-01
US20160272641A1 (en) 2016-09-22
SG11201602723RA (en) 2016-05-30
NZ757220A (en) 2021-12-24
EP3613741A1 (en) 2020-02-26
NZ757222A (en) 2021-12-24
JP2020007366A (ja) 2020-01-16
MX383661B (es) 2025-03-14
RU2019115119A (ru) 2019-05-29
ZA201602054B (en) 2019-06-26
NZ719568A (en) 2018-06-29
EP3067355B1 (en) 2020-12-16
JP6995810B2 (ja) 2022-01-17
MX361659B (es) 2018-12-13
CA2926071C (en) 2021-11-09
IL244969A0 (en) 2016-05-31
JP6617029B2 (ja) 2019-12-04
ES2842225T3 (es) 2021-07-13
BR122022016622B1 (pt) 2023-11-07
AU2014332960A1 (en) 2016-05-26
EP3299370A1 (en) 2018-03-28
CN111153903A (zh) 2020-05-15
US11414417B2 (en) 2022-08-16
DK3067355T3 (da) 2021-01-04
MX2016004506A (es) 2016-06-16
IL289275B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
AR132029A2 (es) Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
AR097744A1 (es) Proceso para producir derivado de diazabiciclooctano y su intermediario
CR20150611A (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis por el virus de la hepatitis b
JO3706B1 (ar) مشتقات H4- بيرولو[2,3-c] بيريدين-4- ون
CR20140238A (es) Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc
CO2017001178A2 (es) Derivado de piridona que tiene un grupo tetrahidropiranil metilo
EA201590321A1 (ru) Дейтерированный барицитиниб
AR096238A1 (es) Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
MX2016004406A (es) Derivados de 1,4-ciclohexilamina y proceso para la preparacion de los mismos.
DOP2020000118A (es) Proceso para la preparación de derivados de quinolina
AR092170A1 (es) Proceso para la fabricacion de benzoxazinonas
MX2016003892A (es) Uso de dihidrooxindolilsulfonamidas sustituidas, o sus sales, para aumentar la tolerancia de plantas al estres.
MX2019005254A (es) Proceso para la purificacion de pirazolpiridazinas.
MX360806B (es) Benzoxazinonas de carbamato.
AR098200A1 (es) Proceso para preparar aluminoxanos, componente catalizador y aluminoxano resultantes
MX388969B (es) Formulas cristalinas de grapiprant.
MX2016013308A (es) Uso de oxotetrahidroquinolinilsulfonamidas sustituidas o sus sales para aumentar la tolerancia al estres en plantas.
WO2016038628A3 (en) A process for preparing olodaterol and intermediates thereof
MX375447B (es) Proceso para fabricar haloacetamidas.
DOP2016000293A (es) Derivados de diheterociclo enlazado a cicloalquilo
BR112016006865A2 (pt) berberinas substituídas e suas sínteses
SA518391413B1 (ar) عملية تحضير وتبلر لليوزيمينول
PH12016501704B1 (en) Method for producing 2-acyliminopyridine derivative
MX350122B (es) Tinturas dispersas, su preparación y su uso.